Please enable Javascript
ASCO 2021
In-depth coverage of the ASCO 2021 Annual Meeting
Restrictive Opioid Prescription Protocol Successfully Reduces Postoperative Opioid Use
GU Oncology Now Editors
ASCO 2021
|
May 7, 2023
The implementation notably reduced the number of opioids that patients were prescribed.
How Does Recurrence of Muscle-Invasive Urothelial Carcinoma Following Radical Surgery Impact HRQoL?
Ariel Jones
ASCO 2021
|
June 11, 2021
The risk of disease recurrence is high among patients with muscle-invasive urothelial carcinoma following radical surgery.
PSMA-Targeted 18F-DCFPyL-PET/CT May Impact Staging in Prostate Cancer
Ariel Jones
ASCO 2021
|
November 30, 2022
In the study, a total of 117 men underwent 18F-DCFPyL-PET/CT.
Interim PSMA PET/CT During 177Lu-PSMA Treatment in mCRPC
Ariel Jones
ASCO 2021
|
November 30, 2022
Staging with PSMA-PET/CT and response classification by Response Evaluation Criteria had prognostic value in prostate cancer.
The Value of Genetic Testing Guidelines in Prostate Cancer
Ariel Jones
ASCO 2021
|
June 6, 2021
Assessing germline variants in patients who did and did not meet the NCCN 2019 PCa germline genetic testing criteria.
TAS0313 Plus Pembrolizumab in Urothelial Carcinoma
Ariel Jones
ASCO 2021
|
June 6, 2021
Evaluating efficacy of a cancer peptide vaccine plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.
Income Plays a Large Role in Prostate Cancer
Ariel Jones
ASCO 2021
|
September 19, 2022
Evaluating the effects of low household income on diagnosis, goals of care, and treatment choice in prostate cancer patients.
Durvalumab Plus Tremelimumab With Concurrent Radiotherapy in Bladder Cancer
Ariel Jones
ASCO 2021
|
June 4, 2021
Researchers evaluated patients with localized MIBC in clinical stages T2-4a who had no contraindications to immunotherapy.
Mediating Racial Disparities in Prostate MRI
Ariel Jones
ASCO 2021
|
September 19, 2022
Racial disparities have been identified in prostate MRI and may affect outcomes for Black men with prostate cancer.
How Has the Pandemic Affected Prostate Cancer Care?
Ariel Jones
ASCO 2021
|
June 4, 2021
A study evaluated trends in outpatient prostate cancer throughout the COVID-19 pandemic using a community-based registry.
Predictive Value of PSMA Protein Expression of Response to Lu-177 PSMA Therapy in Prostate Cancer
Ariel Jones
ASCO 2021
|
November 30, 2022
Is PSMA expression is a reliable predictor of response to Lu-177 PSMA in patients with castration-resistant prostate cancer?
Advertisement
Advertisement
Advertisement
Advertisement